Home|Journals|Articles by Year|Audio Abstracts
 

Original Research

Ann Med Res. 2000; 7(4): 301-305


The Effect Of Etophenamate On The Survival Of Random Pattern Rat Dorsal Skin Flap

İbrahim AŞKAR*,  Ali GÜRLEK**, Bizden T. SABUNCUOĞLU***,  Kutlu SEVİN****

.




Abstract


 


Many skin flaps have been defined for the reconstruction of skin defects. Distal flap necrosis is met as a serious problem especially while elevating long skin flaps. So many experimental and clinical studies have been done to prevent distal flap necrosis and to improve the survival of skin Haps. In this experimental study, the effect of an anti-inflammatory agent, namely etophenamate on skin Hap survival rates has been investigated. In Sprague-Dawiey rats, caudally based random pattern dorsal skin flap including pannicuius carnosus 3x10 cm in size were elevated and sutured back to its original place. In the control group, no pharmacological agent was given, and in the experimental group, etophenamate 10 mg/kg/day, IM, was administered for seven days postoperativeiy. On the seventh day, the surviving areas of the skin flaps were measured and the results were evaluated by Students t-test. The survival rates of skin flaps were found as % 83. 27 in the etophenamate and % 65.70 in the control group. It was found that etophenamate increased the survival rates of skin flaps, statistically significant, comparing to that of control group (p






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.